The Targeted DNA RNA Sequencing Market is rapidly expanding as genomic medicine reshapes the diagnosis and treatment of genetic diseases, cancers, and infectious conditions. Targeted sequencing focuses on specific regions of DNA or RNA, enabling precise detection of mutations, gene expression profiles, and biomarkers critical for personalized medicine.

Advancements in sequencing technologies, bioinformatics, and sample preparation methods have improved accuracy, throughput, and cost-efficiency, making targeted sequencing an attractive choice for researchers, clinicians, and pharmaceutical companies. By focusing on relevant genomic regions, this approach reduces sequencing costs while providing high-value clinical insights.

The market growth is driven by rising demand for precision medicine, cancer diagnostics, prenatal testing, and infectious disease research. Integration with AI and machine learning further enhances data interpretation, enabling rapid decision-making for clinical and research applications.

Challenges include data privacy concerns, standardization issues, and regulatory approvals for clinical use. However, continued technological innovations and increasing adoption across healthcare and research institutions are expected to drive market growth significantly in the coming years.

FAQs
Q1: What is targeted DNA and RNA sequencing?
A1: It is a genomic technique that sequences specific DNA or RNA regions to detect mutations, gene expression, and biomarkers for research and clinical applications.

Q2: Why is this market growing?
A2: Growth is fueled by precision medicine, cancer diagnostics, infectious disease research, and improved sequencing technologies.

Q3: What are the key challenges?
A3: Data privacy, regulatory compliance, and standardization remain major challenges.